News
The agency’s now-reversed decision to halt distribution of a gene therapy for children suffering from muscular dystrophy ...
Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results